- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Emcure Pharmaceuticals Ltd (EMCU)
Emcure Pharmaceuticals Ltd stock price live, this page displays NSE EMCU stock exchange data. View the EMCU premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Emcure Pharmaceuticals Ltd real time stock price chart below.
What Is the Emcure Pharmaceuticals Ltd Stock Price Today?
The Emcure Pharmaceuticals Ltd stock price today is 1,833.50.
What Is the Stock Symbol for Emcure Pharmaceuticals Ltd?
The stock symbol for Emcure Pharmaceuticals Ltd is "EMCU."
What Stock Exchange Does Emcure Pharmaceuticals Ltd Trade On?
Emcure Pharmaceuticals Ltd is listed and trades on the NSE stock exchange.
Is Emcure Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Emcure Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EMCU quote. (ISIN: INE168P01015)
What Is the Emcure Pharmaceuticals Ltd Stock Price Today?
The Emcure Pharmaceuticals Ltd stock price today is 1,833.50.
What Is the Stock Symbol for Emcure Pharmaceuticals Ltd?
The stock symbol for Emcure Pharmaceuticals Ltd is "EMCU."
What Stock Exchange Does Emcure Pharmaceuticals Ltd Trade On?
Emcure Pharmaceuticals Ltd is listed and trades on the NSE stock exchange.
Is Emcure Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Emcure Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EMCU quote. (ISIN: INE168P01015)
1,833.50
-18.00(-0.97%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,816.10
1,899.00
52 wk Range
1,306.50
2,100.70
EMCURE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,816.101,899.00
52 wk Range
1,306.502,100.70
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.19%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.19%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
EMCURE Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
2,229.38
Upside
+21.59%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Prominent player in the Pharmaceuticals industry
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 2,229.38
(+21.59% Upside)
Emcure Pharmaceuticals Ltd Earnings Call Summary for Q1/2027
- Q1 FY2027 revenue rose 22.8% YoY to INR 2,580 crores; EBITDA up 25.8% to INR 508 crores; PAT climbed 36.2% to INR 292 crores.
- International sales drove growth, up 34.2% to INR 1,485 crores; domestic revenue grew 10.2% but organic growth lagged at 6-7%.
- EBITDA margin improved 50 bps to 19.7%; gross margin fell to 58.4% due to higher international mix, expected to settle around 59% for FY2027.
- Management reaffirmed low-to-mid-teens revenue growth guidance for FY2027 with 70-100 bps EBITDA margin expansion; domestic growth expected to improve.
- Net debt to rise to INR 1,450-1,560 crores in Q2 post-acquisitions before targeting net cash by end of FY2028; semaglutide filing in Canada planned.
Last Updated: 2026-08-06, 07:40 a/m
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
15.40 / --
Revenue / Forecast
25.8B / 23.81B
Compare EMCURE to Peers and Sector
Metrics to compare | EMCURE | Peers Peers - average of corresponding metrics from companies closely matching EMCURE: AJANTPHARM, MANKIND, GLENMARK, DIVISLAB, ABBOTINDIA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEMCUREPeersSector |
|---|---|---|---|---|
P/E Ratio | 34.4x | 34.5x | −0.3x | |
PEG Ratio | 0.97 | 1.36 | 0.00 | |
Price/Book | 7.0x | 5.9x | 2.6x | |
Price / LTM Sales | 3.6x | 5.6x | 3.0x | |
Upside (Analyst Target) | 21.6% | 15.0% | 61.4% | |
Fair Value Upside | Unlock | 1.2% | 7.4% | Unlock |
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynaecology, cardiovascular, blood-related, pain and analgesics, oncology/anti-neoplastics, anti-infectives, vitamins, minerals and nutrients, respiratory, HIV antivirals, Metabolics, gastro, anti-diabetic, neuro, derma, and mRNA vaccine. It provides its products under Orofer-Xt, Zostum, Bevon, Amaryl M, Orofer Fcm, Maxtra, Clexane, Metpure-Xl, Amaryl, Spegra, Feronia-Xt, Cardace, Pause, Lornit, Targocid, Orofer-S, Lasilactone, Gros, Orofer-Xt Liq, And Tenectase brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Emcure Pharmaceuticals (EMCURE) Stock Price Today?
The Emcure Pharmaceuticals stock price today is 1,833.50 INR.
What Stock Exchange Does Emcure Pharmaceuticals Trade On?
Emcure Pharmaceuticals is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Emcure Pharmaceuticals?
The stock symbol for Emcure Pharmaceuticals is "EMCURE."
Does Emcure Pharmaceuticals Pay Dividends? What’s The Current Dividend Yield?
The Emcure Pharmaceuticals dividend yield is 0.19%.
What Is the Emcure Pharmaceuticals Market Cap?
As of today, Emcure Pharmaceuticals market cap is 347.78B INR.
When Is the Next Emcure Pharmaceuticals Earnings Date?
Emcure Pharmaceuticals will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is EMCURE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Emcure Pharmaceuticals Stock Split?
Emcure Pharmaceuticals has split 0 times.
How Many Employees Does Emcure Pharmaceuticals Have?
Emcure Pharmaceuticals has 6914 employees.
What is the current trading status of Emcure Pharmaceuticals (EMCURE)?
As of Oct 10, 2026, Emcure Pharmaceuticals (EMCURE) is trading at a price of 1,833.50 INR, with a previous close of 1,833.50 INR. The stock has fluctuated within a day range of 1,816.10 INR to 1,899.00 INR, while its 52-week range spans from 1,306.50 INR to 2,100.70 INR.
What Is Emcure Pharmaceuticals (EMCURE) Price Target According to Analysts?
The average 12-month price target for Emcure Pharmaceuticals is 2,229.38 INR, with a high estimate of 2362 INR and a low estimate of 1900 INR. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +21.59% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.